Amicus Therapeutics, Inc. (FOLD)

10.23 +0.06 (+0.54%) 市場開市。 截至 01:16PM EDT。

Amicus Therapeutics, Inc.

47 Hulfish Street
Princeton, NJ 08542
United States
609 662 2000
https://amicusrx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 517

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Bradley L. Campbell M.B.A.	CEO, President & Director	1.44M	1.31M	1976
Ms. Samantha Prout	Chief Accounting Officer & Controller	無	無	1978
Dr. Jill Weimer Ph.D.	Chief Science Officer	無	無	無
Andrew Faughnan	Senior Director of Investor Relations	無	無	無
Mr. Patrik S. Florencio Esq.	Global Chief Compliance & Risk Officer	無	無	無
Ms. Diana Moore	Head of Global Corporate Communications	無	無	無
Ms. Jayne C. Gershkowitz	Chief Patient Advocate	無	無	1957
Ms. Julie Yu	Chief Program Officer	無	無	1967
Mr. Anthony Sileno	Senior Vice President of Clinical Operations & Translational Sciences	無	無	無
Mr. Simon Jordan	Chief Global Head of Rare Diseases	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

公司管治

截至 2024年4月1日 止，Amicus Therapeutics, Inc. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：8；董事會：3；股東權利：7；現金賠償：5。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。